inhaled prostacyclin
ApprovedSmall molecule
United Therapeuticsinhaled prostacyclin is one of 218 small molecule programs targeting Hypoxemia. It is currently in Approved.
8
Indications
19
Total Trials
4
Active Trials
217
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1inhaled prostacyclin
United TherapeuticsApproved
Veramyst
GSKPreclinical
Flovent
GSKPreclinical
Spiriva
Boehringer IngelheimPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease3 trials
Idiopathic Pulmonary Fibrosis2 trials
Safety and Efficacy2 trials
Pulmonary Arterial Hypertension2 trials
6 more indications
Adult2 trials
PAH2 trials
Interstitial Lung Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for inhaled prostacyclin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company